GlassScriptPhysician profile
John William Vinson
NPI 1063449007
$9,254.70
in general payments reported to CMS, 2019-2025
36 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $1,656 · 2021: $947 · 2022: $1,155 · 2023: $1,336 · 2024: $1,808 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,439.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,471.90 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $1,166.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,130.89 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $926.65 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $840.95 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $801.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $481.99 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.27 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $302.14 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.67 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $209.82 | 2019-2023 | Belsomra, Verquvo, Januvia |
| Esperion Therapeutics, INC. | $161.40 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $118.68 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $114.70 | 2020-2022 | |
| Exact Sciences Corporation | $96.10 | 2023-2025 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $91.18 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $77.45 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $77.10 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $53.40 | 2021-2024 | Yupelri |
| Ironwood Pharmaceuticals, INC | $49.98 | 2020 | |
| Axsome Therapeutics, INC. | $45.99 | 2025 | Symbravo |
| Horizon Therapeutics Plc | $40.75 | 2020 | |
| Allergan, INC. | $37.10 | 2019-2020 | |
| Genentech USA, INC. | $33.48 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.03 | 2024 | Caplyta |
| Eisai INC. | $30.63 | 2020 | |
| Soleno Therapeutics, INC. | $26.94 | 2025 | Vykat Xr |
| Novartis Pharmaceuticals Corporation | $24.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.38 | 2024 | |
| Supernus Pharmaceuticals, INC. | $21.08 | 2023 | Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $20.54 | 2022 | |
| Bausch Health US, LLC | $19.54 | 2020 | |
| Antares Pharma, INC. | $18.76 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.12 | 2024 | Quviviq |
| Agile Therapeutics, INC. | $15.05 | 2021 | |
| Viatris Specialty LLC | $14.23 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.